- BWX Technologies Inc’s (NYSE:BWXT) subsidiary BWXT Medical Ltd. has agreed with Bayer AG (OTC:BAYRY) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products. The financial terms of the agreement were not disclosed.
- The companies to broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other products.
- Ac-225 is a radioisotope used in targeted alpha therapies (TATs), an emerging class of radionuclide therapy for various tumors with a high unmet medical need.
- Bayer’s oncology franchise includes six marketed products, including Xofigo and several other TATs in different stages of development.
- The parties plan to finalize the terms of the commercial agreements at a later date.
- Price Action: BWXT shares traded higher by 1.97% at $55.79 on the last check Thursday.
Related Posts
Why TDCX Shares Are Trading Higher Today
TDCX Inc (NYSE:TDCX) will join the MSCI Global Small Cap Index – Singapore Index. The inclusion will take effect after the…
Credit Suisse Maintains Outperform on Galecto, Lowers Price Target to $7
Credit Suisse analyst Tiago Fauth maintains Galecto (NASDAQ:GLTO) with a Outperform and lowers the price target from $12 to $7.
Citigroup Maintains Buy on Walmart, Lowers Price Target to $166
Citigroup analyst Paul Lejuez maintains Walmart (NYSE:WMT) with a Buy and lowers the price target from $171 to $166.